Blood tests for cancer are here and Guardant Health is leading the charge
Guardant Health has seen a string of consistent firsts - most recently FDA approval for colorectal cancer in July, 2024
Diagnostics
How Seer is using proteomics to revolutionize how we understand complex diseases
Seer's Proteograph Product and Analysis suites are utilizing proprietary nanoparticle technology to help us understand diseases like never before. David Horn, President and CFO, tells us more.
This new blood test could change everything for immunocompromised patients
Alec Ford explains how the Karius Test® uses cutting-edge genomics to detect infections caused by more than 1,000 pathogens within a day of receiving a blood sample, offering a breakthrough for immunocompromised patients, particularly those with cancer.